Custom Harnessing the therapeutic potential of adoptively transferred cells

Date: This event took place on June 22, 2017

Custom webcast sponsor retains sole responsibility for content.

Watch on demand now

In this webcast Dr. Chapuis will describe how her research group has been pursuing adoptive transfer studies in humans with both non- and gene-modified T-cells expressing tumor-specific TCRs for a broad range of targets. She will provide an overview of targeting strategies employed by her group, which have included both self-antigens and oncogenic viruses. She will discuss how they have used cutting-edge technologies, such as the 10x Genomics Chromium System, to help elucidate the reasons for success and failure of adoptive transfer in clinical research subjects and how using these technologies can accelerate development of more effective T-cell therapies.

Specifically, Dr. Chapuis has been looking at Merkel cell carcinoma (MCC), a rare form of skin cancer that is most often the result of a virus called Merkel cell polyomavirus. Chapuis will review her investigation of how the cancer responds to T-cell immunotherapy over time, using scRNAseq to track changes in cell composition over the course of different rounds of treatment. Lastly, Dr. Chapuis will provide a future perspective on how these, and other new approaches, will help to develop new and improved immunotherapies for treating MCC.


  • Prof. Aude Chapuis, MD, Fred Hutchinson Cancer Research Center

    Prof. Aude Chapuis, MD, Fred Hutchinson Cancer Research Center

    Dr. Chapuis is a professor and assistant member of the Clinical Research Division at the University of Washington and Fred Hutchinson Cancer Research Center, Department of Medicine, Division of Medical Oncology. Dr. Chapuis is an expert in hematopoietic stem cell transplantation and in developing novel ways to help a patient’s immune system target life-threatening viral infections and various malignancies. Translational research in Dr. Chapuis’ laboratory is focused on developing novel ways to modulate the immune system to target cancer, better understand factors associated with successful “adoptive” transfer of immune T-cells and developing methods that improve the survival, proliferation and anti-tumor activity of infused T cells to better eliminate tumor targets.

  • Dr. Jayshan Carpen, Springer Nature

    Moderator: Dr. Jayshan Carpen, Springer Nature

    Jayshan is a Senior Publishing Manager for Springer Nature and oversees the custom multimedia unit. Previously he ran science events at the Royal Institution of Great Britain. He received his PhD from the University of Surrey, UK in Neurogenetics. His doctoral thesis focused on identifying polymorphisms associated with diurnal preference and circadian sleep disorders.